Biocon is currently trading at Rs. 471.65, up by 1.25 points or 0.27% from its previous closing of Rs. 470.40 on the BSE.
The scrip opened at Rs. 471.00 and has touched a high and low of Rs. 474.35 and Rs. 470.00 respectively. So far 21109 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 553.70 on 04-Jul-2014 and a 52 week low of Rs. 378.85 on 13-Dec-2013.
Last one week high and low of the scrip stood at Rs. 475.50 and Rs. 453.35 respectively. The current market cap of the company is Rs. 9470.00 crore.
The promoters holding in the company stood at 60.97 % while Institutions and Non-Institutions held 20.00 % and 19.03 % respectively.
Biotechnology firm Biocon and US-based CytoSorbents Corporation have expanded their partnership to develop a therapy intended to treat whole body inflammation caused by various diseases. Biocon will now have the exclusive, region-wide rights to distribute CytoSorb for all critical care applications in the intensive care unit (ICU) as well as cardiac surgery applications for India and select emerging countries. The company will also play a prominent role in the generation of new clinical evidence to support the adoption and usage of CytoSorb.
Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. The company has registered 90.23% rise in its net profit at Rs 181.52 crore for Q2FY15 as compared to Rs 95.42 crore for the same quarter in the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.70 |
| Dr. Reddys Lab | 1220.00 |
| Cipla | 1232.60 |
| Zydus Lifesciences | 928.05 |
| Lupin | 2305.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: